Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Becton Dickinson and Co / Equity Bottom-Up

<ul><li>Becton, Dickinson and Company reported third-quarter fiscal 2026 results that reflected its transition as a focused med tech company following the spin-off of its Life Sciences segment.</li><li>The company generated revenue of $5.0 billion, marking 4.4% growth on a foreign exchange-neutral basis, driven by broad-based strength in over 90% of its portfolio, with many growth platforms expanding at high single to double-digit rates.</li><li>Key contributors included biologic drug delivery (notably GLP-1 therapies), advanced patient monitoring (APM), pharmacy automation via Rowa, pure Wick technology in urgent care, advanced tissue regeneration, peripheral vascular disease products, and strong performance in vascular access and specimen management in the U.S. This growth was partially offset by headwinds concentrated in less than 10% of the portfolio, primarily a challenging prior-year comparison in Alaris infusion systems and ongoing pressures in vaccines within China.</li></ul>

Becton, Dickinson and Company reported third-quarter fiscal 2026 results that reflected its transition as a focused med tech company following the spin-off of its Life Sciences segment.The company generated revenue of $5.0 billion, marking 4.4% growth on a foreign exchange-neutral basis, driven by broad-based strength in over 90% of its portfolio, with many growth platforms expanding at high single to double-digit rates.Key contributors included biologic drug delivery (notably GLP-1 therapies), advanced patient monitoring (APM), pharmacy automation via Rowa, pure Wick technology in urgent care, advanced tissue regeneration, peripheral vascular disease products, and strong performance in vascular access and specimen management in the U.S. This growth was partially offset by headwinds concentrated in less than 10% of the portfolio, primarily a challenging prior-year comparison in Alaris infusion systems and ongoing pressures in vaccines within China.

Becton Dickinson’s $1.7 Billion Cash Engine — Free Cash Flow Jumps 45% But Is It Enough?